CARMEN 2026, a joint call by the European Partnership for Personalised Medicine (EP PerMed), will open on 25 November 2025. Funding organisations from both Israel and Germany are involved in this call.
The European Partnership for Personalised Medicine, EP PerMed, is a platform for the joint planning of national and European regional research and innovation activities. A group of EP PerMed funding organisations from 27 countries (5 of them represented by partners from their regions) has announced the Joint Transnational Call 2026 (JTC2026) “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (acronym: CARMEN2026), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field.
The call will be organised in two phases, i.e. a pre-application phase and a full proposal phase. The budget available for this call is approximately 38 million euros.
Timeline
- 25 November 2025: Publication of the call
- 16 December 2025: Information Day
- 10 February 2026 (14:00, CET): Deadline for pre-proposal submission
- 9 June 2026 (14:00, CEST): Deadline for full proposal submission
Additional Information
Call details are available on the EP PerMed website.
Please direct any inquiries to: eppermed@agencerecherche.fr
An Information Day is scheduled for 16 December 2025 (10:00 bis 12:00 CET).
Registration is now open.